Dr. Lal Path Labs share price
NSE: LALPATHLABBSE: 539524Healthcare ServicesSmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,843.70.
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹30,854 Cr309th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 24 Jul 2026
- 56.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Apr 2026
- 12.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.87%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 24 Jul 2026
- 23.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 24 Jul 2026
- 26.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Apr 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,19,25056.6% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 24 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹798 Crup 13.52%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹171 Crup 28.97%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 21.4%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 24 Oct | Dec 2024Filed 30 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 31 Jul | Sep 2025Filed 31 Oct | Dec 2025Filed 30 Jan | Mar 2026Filed 30 Apr | Jun 2026Filed 24 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 |
| Net profit | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 171 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 19.8% | 16.4% | 25.8% | 20.0% | 20.8% | 13.9% | 18.8% | 21.4% |
Business segments
In the year to Mar 2026 the company reports one business segment which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 51% of 2,464 trading days since Nov 2016.
At or below today's level on 51% of 1,973 trading days since Nov 2018.
At or below today's level on 46% of 1,973 trading days since Nov 2018.
At or below today's level on 88% of 2,476 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +6.9% | +3.4% | +2.4% | 1.1% |
| 3 years | +13.8% | +28.0% | −11.9% | 1.0% |
| 5 years | +0.2% | +11.4% | −10.8% | 0.8% |
Mutual funds holding it
158 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 59 of the 80 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 37
- CutCut. Funds that held fewer shares than at the end of the month before.
- 43
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 73
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 3
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 41,78,451 | 0.76% | ₹830.3 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 25,15,829 | 2.22% | ₹499.9 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 23,50,000 | 1.67% | ₹466.9 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 13,00,000 | 0.64% | ₹258.3 Cr |
 Nippon India Small Cap FundNippon India Mutual Fund | 12,90,970 | 0.32% | ₹256.5 Cr |
 Sundaram Mid Cap FundSundaram Mutual Fund | 11,75,000 | 1.69% | ₹233.5 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 11,46,484 | 0.42% | ₹227.8 Cr |
| HDFC ELSS - Tax Saver FundHDFC Mutual Fund | 11,40,000 | 1.52% | ₹226.5 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 10,00,578 | 2.17% | ₹198.8 Cr |
| HDFC Retirement Fund - EquityHDFC Mutual Fund | 7,00,000 | 2.09% | ₹139.1 Cr |
Peers and competitors
Healthcare Service Provider, 36 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Dr. Lal Path Labs in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Vijaya Diagnostic CentreVIJAYA | 14,311 | 76.3 | 15.0 | 39.4 | +20.2% | +24.9% | 21.4% | 27.8% | 0.14% |
 Metropolis HealthcareMETROPOLIS | 10,849 | 53.8 | 7.2 | 25.6 | +21.8% | +32.6% | 14.2% | 18.6% | 0.38% |
 Thyrocare TechnologiesTHYROCARE | 7,372 | 41.8 | 12.6 | 25.9 | +21.1% | +65.7% | 31.1% | 37.9% | 2.02% |
 Nephrocare Health ServicesNEPHROPLUS | 5,998 | – | 5.4 | – | – | – | – | – | 0.00% |
 Krsnaa DiagnosticsKRSNAA | 1,617 | 16.6 | 1.6 | 8.2 | +10.2% | +21.5% | 10.5% | 8.0% | 0.40% |
 Suraksha DiagnosticSURAKSHA | 1,559 | 43.6 | 6.4 | 15.0 | +23.3% | +8.1% | 15.7% | 24.0% | 0.17% |
 3B Blackbio Dx3BBLACKBIO | 1,145 | 20.6 | 3.5 | 19.6 | +54.3% | +13.2% | 18.7% | 14.1% | 0.37% |
 Health X PlatformHEALTHX | 849 | – | 1.3 | – | +28.8% | – | −3.1% | −9.4% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 30 Jul 2026 | Interim | ₹5.00 |
| 25 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹4.00 |
| 5 Feb 2026 | Interim | ₹3.50 |
| 7 Nov 2025 | Interim | ₹7.00 |
| 6 Aug 2025 | Interim | ₹6.00 |
| 6 Jun 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹6.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
13 Oct · General Updates
12 Oct · General Updates
8 Oct · General Updates
1 Oct · General Updates
Sep 2026
Dr. Lal Path Labs share price by year
Each calendar year to 2025.Dr. Lal Path Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,482.60 | −1.2% | 1,736.75 | 1,155.23 |
| 2024 | 1,500.20 | +16.4% | 1,802.78 | 1,005.53 |
| 2023 | 1,288.85 | +14.0% | 1,371.53 | 889.93 |
| 2022 | 1,130.23 | −40.9% | 1,930.65 | 917.98 |
| 2021 | 1,911.13 | +65.8% | 2,104.30 | 1,117.45 |
| 2020 | 1,152.63 | +54.3% | 1,161.33 | 625.98 |
| 2019 | 746.98 | +64.1% | 838.05 | 456.53 |
| 2018 | 455.15 | +3.3% | 539.48 | 403.55 |
| 2017 | 440.65 | −17.7% | 559.63 | 368.68 |
| 2016 | 535.48 | +33.1% | 623.98 | 360.18 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,839.00 | 1,854.60 | 1,801.20 | 1,838.20 | 1,832.33 | 1,19,250 | 56.6% |
| 22 Oct 2026 | 1,835.00 | 1,857.60 | 1,824.10 | 1,843.70 | 1,838.10 | 3,49,768 | 70.2% |
| 21 Oct 2026 | 1,843.70 | 1,873.10 | 1,819.90 | 1,836.10 | 1,850.86 | 2,91,322 | 75.7% |
| 19 Oct 2026 | 1,856.00 | 1,876.10 | 1,828.40 | 1,843.70 | 1,843.14 | 1,90,469 | 63.3% |
| 16 Oct 2026 | 1,880.00 | 1,907.90 | 1,851.90 | 1,859.90 | 1,871.66 | 2,45,047 | 66.1% |
| 15 Oct 2026 | 1,934.00 | 1,936.80 | 1,856.80 | 1,885.10 | 1,884.83 | 2,18,448 | 59.6% |
| 14 Oct 2026 | 1,910.60 | 1,942.00 | 1,887.10 | 1,938.00 | 1,913.47 | 2,23,891 | 51.7% |
| 13 Oct 2026 | 1,969.70 | 1,988.70 | 1,893.00 | 1,910.60 | 1,923.86 | 95,924 | 48.7% |
| 12 Oct 2026 | 1,933.00 | 2,002.50 | 1,930.00 | 1,969.70 | 1,975.60 | 1,91,545 | 53.9% |
| 9 Oct 2026 | 1,898.90 | 1,942.80 | 1,882.80 | 1,933.60 | 1,914.83 | 1,67,905 | 59.5% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 19 Dec 2025 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
About Dr. Lal Path Labs
Dr. Lal PathLabs Limited provides diagnostic services in India. Its customers are individual patients, hospitals and other healthcare providers, and corporates. Its catalogue lists 525 test panels, 3,130 pathology tests and 1,173 radiology and cardiology tests as on 31 March 2026.
The company delivers these services through an integrated network of reference laboratories, hub labs, cluster labs, satellite labs, patient service centres and franchisee partnerships. As on 31 March 2026 the network had 312 clinical labs, including the National Reference Lab at Delhi and regional reference labs at Kolkata, Bangalore and Mumbai, along with 7,727 patient service centres and 13,935 pick-up points. In the year to March 2026 it collected and processed about 94.5 million samples from 30.3 million patients. In that year it added 14 laboratories and more than 1,100 collection centres, and its network reaches Tier 3 and Tier 4 markets. Outside India, it opened a laboratory in Nepal and another in Bangladesh.
The business was founded in 1949 by Dr. Major S. K. Lal, and grew from a single pathology laboratory into a national network. It was incorporated in 1995, and its shares are listed on the NSE and BSE. It later acquired Suburban Diagnostics, which added to its presence in Western India. It has also launched Sovaaka, an AI-powered precision health screening platform. Its testing menu includes genomic and molecular diagnostics, supported by next generation sequencing capabilities.
- Legal name
- Dr. Lal Path Labs Ltd.
- NSE symbol
- LALPATHLAB
- BSE code
- 539524
- ISIN
- INE600L01024
- Industry
- Healthcare Services
- Listed
- Dec 2015
- Face value
- ₹10
- CIN
- L74899DL1995PLC065388
- Corporate identity number, the registrar of companies' code for it